在６４４０例应用雷米封等抗结核药物的患者中，共有６４９例肝功异常或肝炎表现，占总数的１０．０８％，女性服药者发病率１１．０８％，高于男性组（９．１５％）；肝损害发病率青、中年组最高（１０．４２％和１２．２５％），儿童组相对较少（７．６７％），老年组最低（３．５５％），差别具有统计学意义（Ｐ＜０．０１或Ｐ＜０．０５），肝损害在服药一个月后发病率明显上升；肝损害的类型主要为单项肝功能的异常为８７．６７％，另有１０．９４％表现为无黄疸性肝炎，少数病人可出现肝细胞性黄疸（０．７７％），肝内胆汁淤滞（０．４６％）及急性肝坏死（０．１５％）。 There were 649 cases of liver function abnormalities or hepatitis in 6440 patients receiving antimicrobials such as Remy, accounting for 10.08% of the total. The incidence of female drug users was 11.08%, higher than that of the male group (9.9%). 15%). The incidence of liver damage was higher in middle age group (10.42% and 12.25%) than in middle age group (7.67%) and lowest age group (3.55% Statistical significance (P <0.01 or P <0.05) showed that the incidence of liver damage was significantly increased one month after medication. The main types of liver damage were single liver function abnormalities of 87.67% and another 10. 94% showed no jaundice hepatitis, a small number of patients with hepatocellular jaundice (0.77%), intrahepatic cholestasis (0.46%) and acute hepatic necrosis (0.15%).